madman
Super Moderator
http://www.sciencedirect.com/science/article/pii/S2050052117300410?via=ihub
[h=3]Conclusion[/b]
[h=3]Conclusion[/b]
Short-acting injectable testosterone is associated with greater risk of erythrocytosis compared with other formulations. The mechanism of the pathophysiology and its role on thromboembolic events remain unclear, although some data support an increased risk of cardiovascular events resulting from testosterone-induced erythrocytosis.
Last edited by a moderator:
